ライフサイエンスコーパス: FAAH

1 FAAH did not differ significantly between patients with

2 FAAH exhibited marked differences across brain regions (

3 FAAH inactivation promotes beneficial effects upon pain

4 FAAH inhibition also attenuated autonomic stress reactiv

5 FAAH inhibition produced a 10-fold increase in baseline

6 FAAH inhibition, however, does not increase PEA levels i

7 FAAH inhibitors dampen seizure activity in animal models

8 FAAH inhibitors have shown analgesic and antiinflammator

9 FAAH inhibitors may be useful in treating many disorders

10 FAAH Pro129/Pro129 homozygotes, who constitute nearly ha

11 FAAH(-/-) mice were also prone to diet-induced hepatic i

12 grading enzyme fatty acid amide hydrolase-1 (FAAH-1), termed FAAH-like anandamide transporter (FLAT),

13 Pretreatments with a FAAH inhibitor demonstrated that 80-95% of brain uptake

14 Thus, the AEA/FAAH pathway is an important mediator of HPV and is invo

15 Nearly all FAAH inhibitors known to date attain their binding poten

16 ability of acute stress to modulate amygdala FAAH and AEA in both rats and mice is also mediated thro

17 otype accompanied by elevations in amygdalar FAAH activity and reduced dialysate N-arachidonoylethano

18 A human FAAH 385C->A substitution encodes an FAAH enzyme with reduced catabolic efficacy.

19 Thus, oral administration of an FAAH inhibitor during a brief stress prevents the early

20 we confirmed that oral administration of an FAAH inhibitor during stress prevents the increase in sy

21 e reversed by intra-BLA administration of an FAAH inhibitor.

22 study, healthy adults were randomized to an FAAH inhibitor (PF-04457845, 4 mg orally, once daily; n

23 Treatment with an FAAH inhibitor relieves sensitized glutamatergic respons

24 sms associated with differential anandamide (FAAH rs324420) and CRF1 (CRHR1 rs110402) signaling modul

25 amined the influence of dysregulated CRF and FAAH systems in altering excitatory transmission in the

26 rements of blood-brain barrier diffusion and FAAH substrate recognition.

27 Much like cannabinoid ligands and FAAH inhibitors, PPARgamma agonists show antiproliferati

28 indings support the idea that joint MAGL and FAAH inhibition represents a promising approach for the

29 Dual blockade of both PM20D1 and FAAH reveals a dramatic and non-additive biochemical eng

30 gnificance of these metabolites in vivo, and FAAH mutants may offer opportunities to address this in

31 ancing the enzymatic activity of Arabidopsis FAAH (AtFAAH).

32 tinct from those of the only other available FAAH structure (rat).

33 and second-generation O-arylcarbamate-based FAAH inhibitors, URB597 (cyclohexyl carbamic acid 3'-car

34 Both FAAH inhibitors: (1) blocked FAAH activity in brain and liver, increasing levels of e

35 od and brain FAAH inhibition, allowing blood FAAH activity to be used as a target biomarker.

36 Both FAAH inhibitors: (1) blocked FAAH activity in brain and

37 s in the potency and selectivity toward both FAAH and MAGL.

38 Brain FAAH binding was measured with positron emission tomogra

39 Although brain FAAH may be the relevant target for inhibition, rat stud

40 s show a correlation between blood and brain FAAH inhibition, allowing blood FAAH activity to be used

41 However, the status of brain FAAH in cannabis use disorder is unknown.

42 This first study of brain FAAH in psychosis indicates that FAAH may represent a bi

43 muM; IC(50) (30) = 0.68 muM), and rat brain FAAH (IC(50) (8) = 5.1 muM; IC(50) (30) = 0.29 muM).

44 Anandamide is degraded by FAAH and primarily works by activating two G-protein-cou

45 es an anxious phenotype that is prevented by FAAH inhibition.

46 naptic inhibition, this was not prevented by FAAH inhibition.

47 This was reversed by FAAH inhibitors or exogenous NAE substrate.

48 the reactivation mechanism of carbamoylated FAAH is investigated by means of a quantum mechanics/mol

49 Complete FAAH inhibition blocks only a subset of withdrawal signs

50 and Cox-2 (median inhibitory concentration: FAAH, 0.031 +/- 0.002 microM; Cox-1, 0.012 +/- 0.002 mic

51 y in substance use disorders should consider FAAH C385A polymorphism.

52 ransmission in the CeA, and dysregulated CRF-FAAH facilitates stress-induced increases in glutamaterg

53 d increased hepatic AEA levels and decreased FAAH activity are absent in SCD1(-/-) mice, and the mono

54 andidate inhibitors exhibited time-dependent FAAH inhibition and noncompetitive irreversible inactiva

55 e developed a subset of nanomolar dialyzable FAAH inhibitors (5v-z), functionalized by specific polye

56 SLC6A3, BDNF, SLC6A4, CSNK1E, SLC6A2, DRD2, FAAH, COMT, OPRM1).

57 s 9 and 19 were identified as effective dual FAAH/ChE inhibitors, with well-balanced nanomolar activi

58 nesterase system, and achieve effective dual FAAH/cholinesterase inhibitors.

59 inhibitor JZL184, as well as the novel dual FAAH-MAGL inhibitor SA-57, which is 100-fold more potent

60 nformation that may guide the design of dual FAAH-COX inhibitors with superior analgesic efficacy.

61 Elevations in CRF-CRF1 signaling dysregulate FAAH activity, and this genotypic difference is normaliz

62 Moreover, either FAAH(-/-) mice or wild-type mice treated with FAAH inhib

63 t diet-derived MUFAs, function as endogenous FAAH inhibitors mediating the HFD-induced increase in he

64 w compounds have been described that enhance FAAH activity.

65 These data establish FAAH as a second intracellular pathway for N-acyl amino

66 and functional relationship among eukaryotic FAAH orthologs and features that contribute to versatili

67 tent with this, carriers of a low-expressing FAAH variant (385A allele; rs324420) exhibited quicker h

68 that the compound is a covalent modifier for FAAH and inhibits its action in an irreversible manner.

69 ed or enhanced the intrinsic selectivity for FAAH versus other serine hydrolases.

70 aurine [NAT(20:0)]-as primary substrates for FAAH in mouse skin, and show that the levels of these su

71 tudy was to determine whether combined, full FAAH inhibition and partial MAGL represents an optimal s

72 in people homozygous for a loss-of-function FAAH mutation are associated with a similar phenotype, s

73 mice pure oleic acid fail to inhibit hepatic FAAH activity.

74 events the diet-induced reduction of hepatic FAAH activity, normalizes hepatic AEA levels, and improv

75 A human FAAH 385C->A substitution encodes an FAAH enzyme with re

76 Using recombinant rat and human FAAH, we show that 5-(4-hydroxyphenyl)pentanesulfonyl fl

77 s not inhibit the enzymatic actions of human FAAH, and thus FAAH inhibition cannot account for the ob

78 A functional polymorphism in the human FAAH gene is linked to obesity and mice lacking FAAH sho

79 we hypothesized that variation in the human FAAH gene would predict individual differences in amygda

80 in the gene for fatty acid amide hydrolase (FAAH) (C385A; rs324420), the primary catabolic enzyme fo

81 n an increase in fatty acid amide hydrolase (FAAH) activity and a reduction in the concentration of t

82 A decrease in fatty acid amide hydrolase (FAAH) activity increases the levels of endogenous analog

83 ctivity at human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R).

84 dentification of fatty acid amide hydrolase (FAAH) as a second intracellular N-acyl amino acid syntha

85 lipase (MAGL) or fatty acid amide hydrolase (FAAH) attenuates naloxone-precipitated opioid withdrawal

86 Fatty acid amide hydrolase (FAAH) controls brain anandamide levels; however, it is u

87 on of the enzyme fatty acid amide hydrolase (FAAH) counteracts reward-related effects of nicotine in

88 Fatty acid amide hydrolase (FAAH) degrades 2 major classes of bioactive fatty acid a

89 Fatty acid amide hydrolase (FAAH) degrades NAE into ethanolamine and free fatty acid

90 Fatty acid amide hydrolase (FAAH) degrades the endocannabinoid anandamide, which att

91 or hydrolyzed by fatty acid amide hydrolase (FAAH) during normal seedling establishment, and this con

92 to inhibition of fatty acid amide hydrolase (FAAH) facilitates fear extinction and protects against t

93 rminating enzyme fatty acid amide hydrolase (FAAH) from Arabidopsis in its apo and ligand-bound forms

94 Fatty acid amide hydrolase (FAAH) hydrolyzes the endocannabinoid anandamide and othe

95 catabolic enzyme fatty acid amide hydrolase (FAAH) in the basolateral complex of amygdala (BLA) is th

96 e 1 trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the death of one volu

97 nd that both the fatty acid amide hydrolase (FAAH) inhibitor URB597 and the synthetic cannabinoid ago

98 infusions of the fatty acid amide hydrolase (FAAH) inhibitor URB597, which selectively increases AEA

99 rally restricted fatty acid amide hydrolase (FAAH) inhibitor URB937 (3, cyclohexylcarbamic acid 3'-ca

100 -ketoheterocycle fatty acid amide hydrolase (FAAH) inhibitors are disclosed that additionally and irr

101 rtant classes of fatty acid amide hydrolase (FAAH) inhibitors that carbamoylate the active-site nucle

102 these lipids by fatty acid amide hydrolase (FAAH) is a key regulatory point in NAE signaling activit

103 Fatty acid amide hydrolase (FAAH) is one of the main enzymes responsible for the deg

104 Fatty acid amide hydrolase (FAAH) knockout mice are prone to excess energy storage a

105 olized by either fatty acid amide hydrolase (FAAH) or by lipoxygenase (LOX) to low levels during seed

106 Fatty acid amide hydrolase (FAAH) plays a key role in regulating the tone of the end

107 al inhibition of fatty acid amide hydrolase (FAAH) produces elevated levels of anandamide (AEA) and p

108 ed activation of fatty acid amide hydrolase (FAAH) reduces AEA, we confirmed that oral administration

109 s CNR1 rs806378, fatty acid amide hydrolase (FAAH) rs324420, and MGLL rs4881.

110 as inhibitors of fatty acid amide hydrolase (FAAH) that additionally target the cytosolic port Cys269

111 t mice devoid of fatty acid amide hydrolase (FAAH) with elevated levels ofN-arachidonyl ethanolamide

112 Fatty acid amide hydrolase (FAAH), a gene in the minimal subcongenic interval genera

113 ethanolamine via fatty acid amide hydrolase (FAAH), although it is unclear whether chronic dysregulat

114 Fatty acid amide hydrolase (FAAH), an amidase-signature family member, is an integra

115 pecific amidase, fatty acid amide hydrolase (FAAH), an enzyme with enriched expression in the CNS.

116 is hydrolysis by fatty acid amide hydrolase (FAAH), and inhibitors of the enzyme were suggested as po

117 is by 2 enzymes: fatty acid amide hydrolase (FAAH), and the less-studied N-acylethanolamine-hydrolyzi

118 selectivity over fatty acid amide hydrolase (FAAH), another endocannabinoid-hydrolyzing enzyme.

119 serine amidase, fatty acid amide hydrolase (FAAH), degrades a heterogeneous family of lipid-derived

120 zymes, including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL), N-acylethanolamin

121 egrading enzyme, fatty acid amide hydrolase (FAAH), prolongs the regulatory effects of endocannabinoi

122 radative enzyme, fatty acid amide hydrolase (FAAH), restored both synaptic and behavioral alterations

123 ive inhibitor of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of fat

124 ng by inhibiting fatty acid amide hydrolase (FAAH), the enzyme that degrades the endocannabinoid anan

125 the gene coding fatty acid amide hydrolase (FAAH), the major degrading enzyme of endocannabinoids, o

126 polymorphism in fatty acid amide hydrolase (FAAH), which alters endocannabinoid anandamide (AEA) lev

127 on of the enzyme fatty acid amide hydrolase (FAAH), which causes a reduction in the endocannabinoid a

128 iction (HPV) via fatty acid amide hydrolase (FAAH)-dependent metabolites.

129 properties, and fatty acid amide hydrolase (FAAH)-mediated hydrolysis is a primary catabolic pathway

130 catabolic enzyme fatty acid amide hydrolase (FAAH).

131 se by the enzyme fatty acid amide hydrolase (FAAH).

132 degrading enzyme fatty acid amide hydrolase (FAAH).

133 damide hydrolase fatty acid amide hydrolase (FAAH).

134 re terminated by fatty acid amide hydrolase (FAAH).

135 catabolic enzyme fatty acid amide hydrolase (FAAH).

136 membrane enzyme fatty acid amide hydrolase (FAAH).

137 ivo inhibitor of fatty acid amide hydrolase (FAAH).

138 X-1), COX-2, and fatty acid amide hydrolase (FAAH).

139 ipase (MAGL) and fatty acid amide hydrolase (FAAH).

140 ted variation in fatty acid amide hydrolase (FAAH, C385A), which metabolizes the cannabis-like endoca

141 Fatty acid amide hydrolase (FAAH, EC 3.5.1.99) is the main enzyme catabolizing endoc

142 anandamide levels; however, it is unknown if FAAH is altered in vivo in psychosis or related to posit

143 l ester) as the most potent brain-impermeant FAAH inhibitor disclosed to date.

144 es are needed to examine possible changes in FAAH binding during prolonged cannabis abstinence and wh

145 nd function were absent in mice deficient in FAAH.

146 were depleted during seedling growth even in FAAH tDNA knock-out plants.

147 e we show that reduced energy expenditure in FAAH(-/-) mice could be attributed to decreased circulat

148 lmonary arteries and strongly reduced HPV in FAAH(-/-) mice and wild-type mice upon pharmacological t

149 NAE-oxylipin metabolites were identified in FAAH fatty acid amide hydrolase seedlings but not in wil

150 greatly improved bioluminescence imaging in FAAH-expressing tissues such as the brain.

151 oncerning the role of this water molecule in FAAH's catalytic mechanism, we determined the structure

152 storage and adiposity, whereas mutations in FAAH are associated with obesity in humans.

153 ization with a D3-specific S-35 riboprobe in FAAH knock-in C385A mice confirmed significantly increas

154 arboring a single-amino acid substitution in FAAH (S268D) that selectively disrupts NAT, but not NAE,

155 of SCD1, palmitoleic and oleic acid, inhibit FAAH activity in vitro at low micromolar concentrations.

156 red to be insufficient to completely inhibit FAAH activity which may have led to suboptimal efficacy.

157 d persist in the brain to completely inhibit FAAH for a prolonged period.

158 ly active agents that simultaneously inhibit FAAH, Cox-1, and Cox-2 with high potency and selectivity

159 ototype 4: (ARN2508) is potent at inhibiting FAAH, Cox-1, and Cox-2 (median inhibitory concentration:

160 h and remain active in the brain, inhibiting FAAH for a sustained period.

161 which is 100-fold more potent in inhibiting FAAH than MAGL, would prevent spontaneous withdrawal in

162 ed to assess the effects of NAAA inhibition, FAAH inhibition, and PEA on macroscopic signs of colon i

163 H gene is linked to obesity and mice lacking FAAH show altered metabolic states, but whether these ph

164 Building on experience with a rat leukocyte FAAH activity assay using [(3)H]AEA, we have developed a

165 Lower FAAH binding levels in the brain may be a consequence of

166 In contrast, lower FAAH predicted greater positive psychotic symptom severi

167 ation of untreated psychosis predicted lower FAAH (F(1,26.95) = 6.03, p = .021, Cohen's f = 0.27, med

168 longed cannabis abstinence and whether lower FAAH binding predates drug use.

169 y new pharmacological tools for manipulating FAAH- and NAE-mediated physiological processes in plants

170 seful pharmacological tools for manipulating FAAH-mediated regulation of NAE signaling in plants or a

171 inhibitors opens a new avenue for modulating FAAH activity through nonmechanism-based inhibition.

172 dronabinol reduces fasting colonic motility; FAAH and CNR1 variants could influence the effects of th

173 Multitarget FAAH/Cox blockade may provide a transformative approach

174 pounds are among the most potent multitarget FAAH/COX inhibitors reported so far in the literature an

175 zimidazoles as unique and potent noncovalent FAAH inhibitors.

176 PF-04457845, a novel FAAH inhibitor, reduced cannabis withdrawal symptoms and

177 pective, we discuss the development of novel FAAH inhibitors able to directly act as PPAR agonists an

178 ron emission tomography scans with the novel FAAH radioligand [(11)C]CURB and structural magnetic res

179 ethanolamides act to enhance the activity of FAAH and may stimulate the turnover of NAEs in vivo.

180 phism impacts the expression and activity of FAAH, thereby increasing anandamide levels.

181 their effects on the hydrolytic activity of FAAH.

182 ck out and pharmacological administration of FAAH inhibitors in rodent models result in analgesic, an

183 ated and compared to that for deacylation of FAAH acylated by the substrate oleamide.

184 tial energy surfaces for decarbamoylation of FAAH covalent adducts, derived from the O-aryl carbamate

185 ve and selective bioluminescent detection of FAAH activity in vitro, in live cells, and in vivo.

186 hat genetic or pharmacological disruption of FAAH activity accelerates skin wound healing in mice and

187 by genetic or pharmacological disruption of FAAH in vivo, we developed an engineered mouse model har

188 The potency and tissue distribution of FAAH inhibitors can be imaged in live mice, and luciferi

189 Further, the anti-anxiety effect of FAAH deletion was recapitulated in rats treated orally w

190 The beneficial effects of FAAH inhibition on fear extinction, as well as stress- a

191 The effects of FAAH inhibition on nicotine self-administration and nico

192 which explains the PPAR-mediated effects of FAAH inhibitors.

193 Moreover, the fear-suppressive effects of FAAH overexpression were also mitigated by intra-BLA adm

194 y reflect an alteration of the expression of FAAH, thus forming the basis for the rational design of

195 table radiotracer for the in vivo imaging of FAAH using PET.

196 hese inhibitors achieve potent inhibition of FAAH activity primarily from shape complementarity to th

197 n or selective pharmacological inhibition of FAAH bidirectionally dysregulates intracellular, but not

198 cancer effects, and indeed the inhibition of FAAH has multiple beneficial effects that are mediated b

199 ta support the hypothesis that inhibition of FAAH has therapeutic potential in the treatment of anxie

200 nd rats, which result from the inhibition of FAAH in peripheral tissues and the consequent enhancemen

201 used to profile the successful inhibition of FAAH in recent clinical trials.

202 Pharmacological inhibition of FAAH reversed the increase in receptor revision, RAG exp

203 t exhibit potent and selective inhibition of FAAH.

204 ly with a novel pharmacological inhibitor of FAAH, JNJ5003 (50 mg per kg per day), during exposure to

205 Several active site-directed inhibitors of FAAH have been identified, but few compounds have been d

206 In animals, chemical inhibitors of FAAH have been used for therapeutic treatment of pain an

207 were prepared and examined as inhibitors of FAAH.

208 s that they raise endogenous brain levels of FAAH substrates to a greater extent and for a much longe

209 We identified nine orthologs of FAAH in the moss Physcomitrella patens (PpFAAH1 to PpFAA

210 fects were specific to the overexpression of FAAH because they were reversed by intra-BLA administrat

211 probe deeper into biochemical properties of FAAH.

212 fasting distal MI in patients, regardless of FAAH rs324420 variant (CA/AA vs CC) (P = .046); the grea

213 reducing the negative feedback regulation of FAAH activity by free ethanolamine.

214 hat is responsible for tighter regulation of FAAH is recent in vertebrates and absent or not fully em

215 ute to versatility and tighter regulation of FAAH.

216 ntify key residues within the active site of FAAH that confer the species-specific sensitivity to inh

217 valent inhibitor, the cocrystal structure of FAAH complexed with compound 2 reveals that these ketobe

218 ic mechanism, we determined the structure of FAAH conjugated to a urea-based inhibitor, PF-3845, to a

219 The X-ray structure of FAAH in complex with the NSAID carprofen, along with sit

220 The substrates of FAAH are also PPAR agonists, which explains the PPAR-med

221 ssion (but not fatty-acid amide hydrolase or FAAH) were more vulnerable to cortical thinning.

222 hydrolase seedlings but not in wild-type or FAAH overexpressors, suggesting that NAE hydroxide pools

223 ogenous brain levels of anandamide and other FAAH substrates upon intraperitoneal (i.p.) administrati

224 Overall, FAAH was higher in female subjects than in male subjects

225 ector to rapidly yet transiently overexpress FAAH specifically within the BLA to assess the impact of

226 Importantly, the assay preserved partial FAAH inhibition resulting from ex vivo treatment with a

227 This plant FAAH structure revealed features distinct from those of

228 AH1 to PpFAAH4 were closely related to plant FAAH while PpFAAH6 to PpFAAH9 were to the rat FAAH, cate

229 tructural and functional properties of plant FAAHs.

230 We have synthesized a series of potent FAAH inhibitors encompassing two classes of N-alkyl-O-ar

231 ed in vitro and ex vivo in rats as potential FAAH imaging agents for positron emission tomography (PE

232 iotracers are required to image and quantify FAAH activity in vivo.

233 ure of 3 bound to a humanized variant of rat FAAH revealed that 3 was not only covalently bound to th

234 AAH while PpFAAH6 to PpFAAH9 were to the rat FAAH, categorized based on the membrane binding cap, mem

235 (JZP-327A, 51), inhibited human recombinant FAAH (hrFAAH) in the low nanomolar range (IC50 = 11 nM),

236 s increased the apparent Vmax of recombinant FAAH proteins from both plant (Arabidopsis) and mammalia

237 Specifically, there is reduced FAAH expression associated with the variant allele that

238 The association of reduced FAAH function with higher dopamine D3 receptors in human

239 1, 2, 4, 5 down-regulated FAAH mRNA expression.

240 ced damage through a mechanism that requires FAAH inhibition.

241 rins CycLuc1 and CycLuc2 or their respective FAAH-sensitive luciferin amides.

242 ated a new series of peripherally restricted FAAH inhibitors and identified compound 35 (cyclohexylca

243 A 10-2474, an orally administered reversible FAAH inhibitor, was given to healthy volunteers to asses

244 emely potent, noncompetitive, and reversible FAAH inhibitors endowed with a remarkable selectivity pr

245 experimental data showing slowly reversible FAAH inhibition for the N-piperazinylurea inhibitor and

246 thermore, we show that in contrast to rodent FAAH, CBD does not inhibit the enzymatic actions of huma

247 ents employing a novel, potent and selective FAAH inhibitor, AM3506 (5-(4-hydroxyphenyl)pentanesulfon

248 3,4-oxadiazol-2-ones as potent and selective FAAH inhibitors has been described.

249 Aiming at discovering new selective FAAH inhibitors, we developed a series of compounds (5a-

250 Strikingly, FAAH inhibition during the traumatic stressor was also e

251 Surprisingly, FAAH overexpression in BLA dampened stress-induced corti

252 icate for whom and for what anxiety symptoms FAAH inhibitors or exposure-based therapies will be most

253 tegies for cannabis use disorder that target FAAH and endocannabinoids.

254 Targeting FAAH activity, therefore, presents a promising new thera

255 atty acid amide hydrolase-1 (FAAH-1), termed FAAH-like anandamide transporter (FLAT), that lacked ami

256 45, a highly selective and clinically tested FAAH inhibitor.

257 the clinical safety profile of other tested FAAH inhibitors, that off-target activities of BIA 10-24

258 mper aspects of the stress response and that FAAH inhibition may aid the treatment for stress-related

259 , may lead to systemic autoimmunity and that FAAH is a lupus-susceptibility gene that might regulate

260 data provide preliminary human evidence that FAAH inhibition can improve the recall of fear extinctio

261 Our data indicate that FAAH deletion, and the resulting increases in NAEs, pred

262 Collectively, these studies indicate that FAAH-mediated decreases in AEA occur following chronic s

263 dy of brain FAAH in psychosis indicates that FAAH may represent a biomarker of disease state of poten

264 These data suggest that FAAH inhibitors may represent a novel class of anxiolyti

265 These studies suggest that FAAH is required for chronic stress to induce hyperactiv

266 nd promotes fear extinction, suggesting that FAAH inhibitors may aid fear extinction-based treatments

267 The FAAH genetic polymorphism (rs324420) and blood, urine, a

268 The FAAH selectivity of the compound 51 over the supposed ma

269 The FAAH-S268D mice accordingly show substantial elevations

270 nts revealed a clear increase of AEA and the FAAH-dependent metabolite arachidonic acid in hypoxic lu

271 s that had shown promising activities at the FAAH-D3R target combination in preliminary studies.

272 Individuals homozygous for the FAAH 385A allele may therefore offer a genetic model to

273 (PET) in 79 human subjects genotyped for the FAAH C385A polymorphism (36/79 AC + AA).

274 A mutation in the FAAH gene that enhances endocannabinoid signaling has be

275 ,000 3- to 21-y-olds, we show effects of the FAAH genotype specific to frontolimbic connectivity that

276 combined administration of high-dose of the FAAH inhibitor PF-3845 and low-dose of the MAGL inhibito

277 iscrimination procedures, and neither of the FAAH inhibitors induced dopamine release in the nucleus

278 Using a knock-in mouse model of the FAAH polymorphism that controls for genetic and environm

279 aimed to test the efficacy and safety of the FAAH-inhibitor PF-04457845 in reduction of cannabis with

280 Here, we report the structure of the FAAH-URB597 complex at 2.3 A resolution.

281 ng the CB1 receptor antagonist AM251, or the FAAH inhibitor URB597, directly into the basolateral amy

282 We found that the FAAH genetic variant C385A was associated with significa

283 ere carried out in 30 knock-in mice with the FAAH C385A polymorphism (20/30 AC + AA).

284 mong IBS with constipation patients with the FAAH CC variant (P = .045).

285 ce in response to chronic treatment with the FAAH inhibitor URB597.

286 noid signaling to therapeutic levels through FAAH inhibition might be beneficial for neurodegenerativ

287 he enzymatic actions of human FAAH, and thus FAAH inhibition cannot account for the observed increase

288 traction measurements showed that binding to FAAH was irreversible and kinetically different for the

289 The results point to FAAH-regulated NAT signaling as an unprecedented lipid-b

290 y constituted binding of the radiotracers to FAAH.

291 In cannabis users, FAAH binding was significantly lower by 14%-20% across t

292 Future studies will utilize FAAH mutants of moss to elucidate the role of anandamide

293 ith diarrhea or alternating with the variant FAAH CA/AA (P = .013).

294 In vitro, FAAH exhibits a more restricted substrate scope compared

295 gnaling in humans, helping to inform whether FAAH inhibitors have the potential to facilitate fear ex

296 However, the molecular mechanism by which FAAH affects energy expenditure (EE) remains unknown.

297 proach to IBD and other pathologies in which FAAH and Cox are overactive.

298 st that Arabidopsis LOXs indeed compete with FAAH to metabolize PU-NAEs during seedling establishment

299 AAH(-/-) mice or wild-type mice treated with FAAH inhibitor URB597 are protected against hypoxia-indu

300 ype mice upon pharmacological treatment with FAAH inhibitor URB597.